As I said in my earlier post I think that risk management is an important consideration and I definitely agree with tada's post.  To me RVX is somewhat unique in that it is not a single molecule opportunity yet one of the biggest current risks, in my mind, is that as shareholders we are at risk of losing any participation in the other compounds if something goes wrong with BetOnMace.  I would agree with Chicago that CVR's do not get the same big number deal that comes with waiting it out AND successful trial completion.  I think however, in the case of RVX that this would be offset by the fact that with a CVR would come no more dilution and a quicker path to exploitation, and thus future potential royalties, of other RVX compounds in addition to Apabetalone .  This in addition to the risk management benefits. 

Chicago you had asked what I thought about the Royalty preferreds that Zenith holds but I'm not sure from what perspective you are asking.